It is known that mutation in transcription factors regulating myeloid differentiation, in particular RUNX1 and CCAAT/enhancer binding protein alpha (C/EBPα) are common in the progression from MDS to secondary AML11–13. Here, CEBPA is linked to myelodysplastic syndrome.